MedPageToday
MedPage Today) — LONDON — Vutrisiran (Amvuttra) improved functional and disease outcomes as well as survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to findings from the HELIOS-B phase III trial.
And the benefits…
Read More
Amyloidosis Drug Improves Outcomes, Survival
Stephania Serna
06:37
MedPage Today) — LONDON — Vutrisiran (Amvuttra) improved functional and disease outcomes as well as survival in transthyretin amyloidosis cardiomyopathy (ATTR-CM), according to findings from the HELIOS-B phase III trial. And the benefits…
